Natera, a genetic testing company, has received approval from the U.S. Food and Drug Administration for its Prospera Lung Transplant Assessment test. The test is a non-invasive blood test that can help predict the risk of rejection in lung transplant patients.
The Prospera test analyzes the genetic information in a patient’s blood to determine if the immune system is attacking the transplanted lung, a condition known as acute rejection. By detecting rejection early, doctors can intervene and adjust the patient’s medication to prevent further damage.
The approval of the Prospera test is a significant advancement in the field of lung transplant medicine, as it provides a less invasive way to monitor and manage rejection in patients. This could improve patient outcomes and help healthcare providers make more informed treatment decisions.
